Status:

COMPLETED

Study Using Deferiprone Alone or in Combination With Desferrioxamine in Iron Overloaded Transfusion-dependent Patients

Lead Sponsor:

Lipomed

Conditions:

Hemochromatosis

Eligibility:

All Genders

4+ years

Phase:

PHASE2

Brief Summary

Systematical (retro- and prospective) investigation of the long-term safety (toxicity assessment according to CTCAE v3.0) and efficacy of deferiprone either given alone or in combination with desferri...

Detailed Description

Patients with refractory anemias requiring regular blood transfusions accumulate iron at the rate of approximately 0.5 mg/kg/day, which may lead to serious organ toxicity, e.g. to the heart, liver and...

Eligibility Criteria

Inclusion

  • Iron overloaded male or female patients with primary or secondary hemochromatosis
  • Age: 4 years and older
  • Patients with desferrioxamine toxicity or allergy (e.g. visual or hearing defects, bone abnormalities, reactions at injection site)
  • Patients unable or unwilling to comply satisfactorily with regular desferrioxamine administration on 5-7 days/week
  • Combination treatment: patients not sufficiently chelated with desferrioxamine or deferiprone monotherapy
  • Patients must be willing to undergo routine screening including medical history, physical examination and hematology, biochemistry and other laboratory tests
  • Written informed consent

Exclusion

  • Children under 4 years of age
  • Female and male of reproductive age, sexually active but not taking adequate contraceptive precaution
  • Woman who are pregnant or breast-feeding
  • Patients with HIV
  • Patients with active hepatitis requiring treatment
  • Patients with severe hepatic failure, cirrhosis
  • Patients with neutropenia (neutrophils less than 1.5 exp9/l, MDS: less than 0.5 exp9/l)
  • Patients with thrombocytopenia (platelets less than 100 exp9/l, MDS: less than 20 exp9/l)
  • Patients with decompensated heart failure (LVEF less than 40% or patients under continuous cardiac medication)
  • Patients with severe renal failure

Key Trial Info

Start Date :

March 1 2005

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 1 2011

Estimated Enrollment :

24 Patients enrolled

Trial Details

Trial ID

NCT00349453

Start Date

March 1 2005

End Date

May 1 2011

Last Update

December 12 2011

Active Locations (13)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 4 (13 locations)

1

Cantonal Hospital, Children's Clinic

Aarau, Canton of Aargau, Switzerland, 5001

2

Cantonal Hospital

Aarau, Canton of Aargau, Switzerland, 5001

3

Private children's practice

Bern, Canton of Bern, Switzerland, 3014

4

Children's Hospital of Eastern Switzerland

Sankt Gallen, Canton of St. Gallen, Switzerland, 9006